ALBANY, N.Y., May 15 /PRNewswire/ -- Valeo Pharma announced today a new study recently published that demonstrated the efficacy and safety of Hydrosal(R), a novel high strength topical antiperspirant with 15% aluminum chloride and 2% salicylic acid in proprietary gel base for patients with moderate-to-severe hyperhidrosis (excessive sweating).
The study, conducted by Katherine Flanagan, MD and Dee Anna Glaser, MD at the Department of Dermatology at Saint Louis University School of Medicine, was published in the May issue of the Journal of Drugs in Dermatology (JDD). Of the thirty patients who were enrolled, 43% had tried high-strength antiperspirants previously. Patients were given Hydrosal and monitored at 4 and 12 weeks for efficacy and tolerability. They were instructed to apply a small amount of the gel at bedtime for seven days and twice per week or as tolerated thereafter.
Overall, 70% of participants demonstrated significant improvement with satisfaction of treatment and Hydrosal was well-tolerated with minimal side effects. Patients who had previously failed other high-strength antiperspirants also reported similar success. They also experienced significant improvements in quality of life including improvement in social and professional situations.
"The key to Hydrosal's effectiveness is the gel base -- it is unique and helps balance high efficacy and tolerability for patients with moderate to severe hyperhidrosis. Valeo is extremely pleased that these results have shown a significant improvement in the quality of life for these patients, so they can enjoy activities more and not have to worry about their excessive sweating," stated Steve Saviuk, President of Valeo Pharma.
To learn more about Hydrosal Professional, please visit www.hydrosalpro.com or contact Valeo Pharma at 866 694-0150.
To see press release go to http://myprgenie.com/1897
CONTACT: Ms. Amy Nesbitt, amy@pascalecommunications.com, +1-412-327-9499
Web site: http://www.hydrosalpro.com/
